WQ5 Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EST
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)833.00
Market Cap
€12.78M
Enterprise Value€11.62M
Total Cash (Recent Filing)€111.79K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding566,409,800
10 Day Avg. Volume2,500
30 Day Avg. Volume833
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-14.33
Price to Sales (P/S)0.00
P/FCF Ratio-5.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Financial DebtHaving zero financial debt lowers immediate refinancing risk and preserves flexibility to raise equity or secure non‑debt funding. Over a 2–6 month horizon this reduces liquidity stress, gives management optionality to fund R&D, and avoids interest burdens that accelerate cash depletion.
Improving Free Cash Flow TrendAn improvement in free cash flow year‑on‑year suggests the company may be improving operational efficiency or moderating cash burn. If sustained, this trend extends runway, lowers near‑term financing needs, and materially improves the firm's ability to progress clinical programs over the medium term.
Focus On Ageing Gene TherapiesGenflow’s emphasis on gene‑based approaches for ageing and sirtuin biology targets a large, structural market driven by demographic ageing and chronic disease prevalence. A clear scientific niche can create durable differentiation and attractive long‑term market opportunities if programs translate clinically.
Bears Say
Pre-revenue And Operating LossesBeing pre‑revenue with persistent operating losses and negative gross profit means the company lacks internal cash generation and must repeatedly access external capital. This structurally constrains the pace of development, increases execution risk for pipelines, and raises dilution probability over the medium term.
Negative Shareholders' EquityShareholders’ equity turning negative across consecutive years signals accumulated losses have overwhelmed the capital base. Negative equity is a material structural weakness that can limit financing alternatives, weaken partner confidence, and complicate licensing or collaboration negotiations.
Consistent Cash Burn And Funding DependencePersistent negative operating and free cash flow and stated dependence on external funding create a structural financing vulnerability. Reliance on equity raises or grants increases dilution risk and can delay or disrupt R&D timelines if capital markets or sponsors are constrained over the next several months.
Genflow Biosciences Plc News
WQ5 FAQ
What was Genflow Biosciences Plc’s price range in the past 12 months?
Genflow Biosciences Plc lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is Genflow Biosciences Plc’s market cap?
Genflow Biosciences Plc’s market cap is €12.78M.
When is Genflow Biosciences Plc’s upcoming earnings report date?
Genflow Biosciences Plc’s upcoming earnings report date is Sep 25, 2026 which is in 72 days.
How were Genflow Biosciences Plc’s earnings last quarter?
Genflow Biosciences Plc released its earnings results on Apr 30, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is Genflow Biosciences Plc overvalued?
According to Wall Street analysts Genflow Biosciences Plc’s price is currently Overvalued.
Does Genflow Biosciences Plc pay dividends?
Genflow Biosciences Plc does not currently pay dividends.
What is Genflow Biosciences Plc’s EPS estimate?
Genflow Biosciences Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genflow Biosciences Plc have?
Genflow Biosciences Plc has 566,409,800 shares outstanding.
What happened to Genflow Biosciences Plc’s price movement after its last earnings report?
Genflow Biosciences Plc reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Genflow Biosciences Plc?
Currently, no hedge funds are holding shares in DE:WQ5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genflow Biosciences Plc
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.
Technical Analysis
Oxford BioDynamics
―
Physiomics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―